Privately owned Oxford Nanopore offers a range of tools and and instruments based on a proprietary nanopore-based DNA and RNA sequencing technology.
A meta-analysis involving 16,595 women with leiomyoma and 523,330 without led to 16 associated loci related to both tumorigenesis and estrogen-related traits.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
Analyzing samples from Iceland and elsewhere, researchers uncovered one known and two new risk loci for aortic valve stenosis that are also associated with other heart risk pathways.
A Decode Genetics-led team found that parental genotype influences children's education attainment even if the kids don't inherit those alleles.
Amgen will use BC Platforms' tools and services to study data in multiple indications, including cardiovascular and bone diseases, hematological malignancies, and other cancers.
The companies are aiming to develop Idylla-based CDx biomarker tests for a compound Amgen is developing to treat solid tumors.
The companies are seeking to register Biocartis' Idylla RAS biomarker tests with the FDA as companion diagnostics for Amgen's Vectibix.
Adaptive Biotechnologies will measure minimal residual disease in multiple myeloma patients as part of an Amgen-sponsored clinical trial.
The one-year partnership will focus on identifying patients with abnormal pain conditions and validating the genetic findings as potential targets for drugs.
This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.
The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.
Researchers find that people's genetics influence their success at university, but that it is not the only factor.
In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.